ArticleCureus2025
Pelizaeus-Merzbacher Disease as a Cause of Early-Onset Developmental Delay: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal rehabilitation in PLP1-associated spastic paraparesis: a case report with clinical and biomechanical outcomes.Frontiers in rehabilitation sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pelizaeus-Merzbacher disease (PMD) is a rare X-linked hypomyelinating leukodystrophy disorder caused by a mutation in the proteolipid protein 1 (PLP1) gene which is responsible for myelin formation in the central nervous system. We report a case of PMD in a male patient who initially presented with developmental delay at three months and was ultimately diagnosed at 10 years and 7 months of age. We aim to describe the initial presentation, clinical course of PMD and the investigations that aid in diagnosis so that future cases may be identified earlier. During the investigative workup of our patient, a deletion of exon 16 - an extremely rare heterozygous nucleotide variation, c.330C>T (p.D110D) - was identified, the pathogenicity of which has not been previously documented in the literature. In our report, we also aim to highlight the potential use of biotin in improving symptoms in such patients as there is currently no curative treatment available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.